Fractyl Health (NASDAQ:GUTS - Get Free Report) is set to announce its earnings results after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors that wish to listen to the company's conference call can do so using this link.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings data on Monday, April 1st. The company reported ($8.02) EPS for the quarter. The company had revenue of $0.01 million for the quarter. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fractyl Health Trading Down 4.7 %
NASDAQ GUTS traded down $0.30 during midday trading on Wednesday, hitting $6.06. 191,006 shares of the company traded hands, compared to its average volume of 330,103. Fractyl Health has a 52 week low of $5.75 and a 52 week high of $14.50. The firm has a 50-day simple moving average of $7.23.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the company. Morgan Stanley began coverage on Fractyl Health in a research note on Tuesday, February 27th. They issued an "overweight" rating and a $18.00 target price on the stock. Evercore ISI began coverage on shares of Fractyl Health in a research note on Wednesday, February 28th. They set an "outperform" rating for the company. Finally, Bank of America started coverage on shares of Fractyl Health in a research report on Tuesday, February 27th. They set a "buy" rating and a $26.00 target price for the company.
View Our Latest Research Report on Fractyl Health
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
See Also
Before you consider Fractyl Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fractyl Health wasn't on the list.
While Fractyl Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
